Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | SCN1A | P35498 | 2/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL27927616 | 0.88 | CYP1A2 (0.55) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL6551622 | 0.84 | KCNA5 (0.51) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL28254705 | 0.81 | KCNA5 (0.49) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL6355812 | 0.81 | SLC6A2 (0.47) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL29031285 | 0.80 | KCNA5 (0.47) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| Bromide SCHEMBL9522591 | 0.79 | SLC6A2 (0.45) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL5622980 | 0.79 | KCNA5 (0.50) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL177936 | 0.79 | SLC6A2 (0.45) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL29520435 | 0.78 | TSHR (0.62) | KCNA5KCNH2TSHRCYP2D6KCNE1 | |
| SCHEMBL3910230 | 0.78 | TSHR (0.62) | KCNA5KCNH2TSHRCYP2D6KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1814877-B1 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| CN-101039938-A | Diphenyl substituted alkanes as flap inhibitors | MERCK & CO INC (US) | 2007-09-19 | — | — | CN | disclosed |
| EP-1814877-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006044602-A9 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO INC (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006044602-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | KCNA5 938/4885KCNH2 807/4885TSHR 170/4885 |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | KCNA5 3702/4885KCNH2 4455/4885TSHR 4574/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | ALOX5, ALOX15, ALOX15B | KCNA5 3782/4885KCNH2 3950/4885TSHR 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.